Tag: M.W=400-600

Kirmizi, N. Ipek; Aydin, Volkan; Akici, Narin; Bayar, Banu; Akici, Ahmet published the artcile< Utilization of biotechnological drugs in rare diseases requiring the use of off-label drugs in children in Turkey>, Quality Control of 1492-18-8, the main research area is biotechnol drug rare disease OLDU child; biotechnological drugs; canakinumab; pediatrics; rare disease; Off-label drug use.

Pediatric patients, especially those with rare diseases, represent a population that has a high tendency towards offlabel drug use (OLDU) and needs a more careful practice of pharmacotherapy than in adults. We aimed to investigate biotechnol. drug use in children with rare diseases requiring OLDU. This retrospective study examined all single-diagnosed OLDU applications (n = 5792) for 4992 children (<18-yr) in Turkey. Applications of rare diseases were selected, and their descriptive characteristics were examined, including demog. features of patients, biotechnol. drug utilization status, and disease categories. The off-label statuses of the drugs at the end of 2020 were also examined In total, 77.7% (n = 4501) of OLDU applications were made for rare diseases. Biotechnol. drug use was higher in rare disease applications than in nonrare diseases (37.9% vs. 19.2%, resp.; p < 0.0001). Canakinumab was the top applied biotechnol. drug (73.2%). Compared to that in small-mol. drugs, the mean age of patients was higher in biotechnol. drug-containing applications (8.1 ± 5.3 vs. 9.7 ± 4.9, resp.; p < 0.0001). Biotechnol. drug use was higher in nonneoplastic rare diseases (40.3%) than in neoplastic rare diseases (26.4%), (p < 0.0001). At the end of 2020, the approval status of the off-label indications covered in 2016 was significantly higher for rare (24.4%) vs. nonrare (5.2%, p < 0.0001) diseases and for biotechnol. (32.3%) vs. smallmol. (13.9%, p < 0.0001) drugs. In total, 87.7% of the drugs would have to be still used in the off-label setting at the end of 2020. It was seen that more than three-quarters of the pediatric OLDU applications are for rare diseases, and the need for biotechnol. OLDU in this group is almost 2-fold of small-mol. drug use. While further projected findings imply a higher approval tendency for rare diseases and biotechnol. drugs, there seems to be more room for improvement for pediatric drug use. Turkish Journal of Medical Sciences published new progress about Blood. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Quality Control of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Guo, Guifang; Chen, Xiuxing; Cai, Xiuyu; Chen, Yanfeng; Wang, Haohua; Fan, Lei; Bai, Long; Qiu, Huijuan; Zhang, Bei published the artcile< Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy>, Related Products of 1492-18-8, the main research area is colorectal cancer anticancer agent metastasis; C-reactive protein (CRP); Colorectal cancer; carbohydrate antigen 19-9 (CA 19-9); carcinoembryonic antigen (CEA); geriatric patient; inflammation; lactate dehydrogenase (LDH); neutrophil-to-lymphocyte ratio (NLR).

A total of 186 MCRC patients aged =65 years, receiving chemotherapy between Jan. 1, 2004 and Oct. 1, 2015 were identified. Pretreatment levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), LDH, CRP and NLR were measured. Effect of these inflammatory factors on overall survival (OS) and first-line progression-free survival were analyzed. Median PFS and OS were 6.70 mo and 25.62 mo. CEA =85 ng/mL (P=0.010), CA 19-9 =32.97 U/mL (P=0.010), LDH =325 U/L (P=0.015), CRP =11 mg/L (P=0.004) and NLR =2.12 (P=0.045) were associated with poor OS. Furthermore, LDH (P=0.025) was demonstrated as an independent prognostic factor of OS for all patients, so did the combination of CEA with CA 19-9 (P=0.009). When predicting the one, three and five-year survival, combination of CEA with CA 19-9 had higher sensitivity compared with CEA alone or CA 19-9 alone resp. For right-sided colon cancer, CEA (P<0.001) and CA 19-9 (P=0.003) were related with OS and CEA (P=0.002) was the independent prognostic factor. For left-sided colorectal cancer, inflammatory factors related with OS were LDH (P=0.039), CRP (P=0.004) and NLR (P=0.020) and CRP (P=0.040) was the independent prognostic factor. However, no inflammatory factors were contained in multivariate COX regression. CEA, CA 19-9, LDH, CRP and NLR were related with OS in geriatric patients with MCRC. Right-sided and left-sided groups had different independent prognostic markers, CEA and CRP resp. Translational Cancer Research published new progress about Biomarkers. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Related Products of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Takabatake, Kazuya; Arita, Tomohiro; Nakanishi, Masayoshi; Kuriu, Yoshiaki; Murayama, Yasutoshi; Shimizu, Hiroki; Kudou, Michihiro; Kiuchi, Jun; Kosuga, Toshiyuki; Konishi, Hirotaka; Morimura, Ryo; Shiozaki, Atsushi; Ikoma, Hisashi; Kubota, Takeshi; Fujiwara, Hitoshi; Okamoto, Kazuma; Otsuji, Eigo published the artcile< Impact of inferior mesenteric artery lymph node metastasis on the prognosis of left-sided colorectal cancer>, Safety of Calcium folinate, the main research area is colorectal cancer prognosis inferior mesenteric artery lymph node metastasis; Colorectal cancer; distant lymph node metastasis; inferior mesenteric artery lymph node metastasis; lateral pelvic lymph node metastasis; para-aortic lymph node metastasis; prognosis.

This study aimed to investigate the impact of the inferior mesenteric artery (IMA) lymph node metastasis [IMALN (+)] on prognosis in left-sided colorectal cancer (LCRC). A total of 285 patients with stage III LCRC and 118 patients with stage IV LCRC who underwent resection of primary tumor between 2005 and 2016 were included. IMALN (+) patients (n = 10) had worse overall survival (OS) than patients without IMA lymph node metastasis [IMALN (-); n = 275] in stage III LCRC (p = 0.007). Multivariate anal. revealed that IMALN (+) was a prognostic factor in stage III LCRC (OS, HR = 3.09, p = 0.043). Conversely, there was no difference between the OS of IMALN (+) and stage IV LCRC with distant lymph node metastasis only [stage IV LCRC (LYM); n = 21; p = 0.434]. The prognosis of IMALN (+) was worse than that of IMALN (-); it was similar to that of stage IV LCRC (LYM).

Anticancer Research published new progress about Antitumor agents. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Safety of Calcium folinate.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Loznjak, Petra; Striegel, Lisa; Diaz De la Garza, Rocio I.; Rychlik, Michael; Jakobsen, Jette published the artcile< Quantification of folate in food using deconjugase of plant origin combined with LC-MS/MS: A method comparison of a large and diverse sample set>, Recommanded Product: Calcium folinate, the main research area is folate food plant glutamyl hydrolase LC MS; 10-Formylfolic acid (PubChem CID: 3080544); 5,10-Methenyltetrahydrofolate (PubChem CID: 439237); 5-Formyltetrahydrofolate (PubChem CID: 149436); 5-Methyltetrahydrofolate (PubChem CID: 439234); Deconjugase enzymes; Folates; Folic acid (PubChem CID: 6037); Food; LC-MS/MS; Method comparison; Microbiological assay; Tetrahydrofolate (PubChem CID: 1129).

A round robin comparison was performed in order to test the performance of a recently developed LC-MS/MS method for quantification of 6 folate forms. Eighty-nine samples representing the food groups of fruits, vegetables, legumes, cereals, dairy products, meat, and offal were analyzed by two LC-MS/MS methods and a microbiol. assay (MA). A plant-origin deconjugase enzyme (Arabidopsis thaliana) for deconjugation of folates (PE-LC-MS/MS), or animal-origin deconjugase (rat serum and chicken pancreas) (AE-LC-MS/MS) was used in the LC-MS/MS methods, each in a single enzymic step. In contrast, the MA involved tri-enzyme extraction including human plasma as a deconjugase. A significant bias of 17% lower and 25% higher results was found when PE-LC-MS/MS was compared to MA and AE-LC-MS/MS, resp. The PE-LC-MS/MS provides fast quantification of various folate vitamers and total folate content, which could be a proper substitute to the currently standardized but imprecise and time-consuming microbiol. assay in the future.

Food Chemistry published new progress about Allium cepa. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Recommanded Product: Calcium folinate.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Hata, Taishi; Hagihara, Kiyotaka; Tsutsui, Anna; Akamatsu, Hiroki; Ohue, Masayuki; Shingai, Tatsushi; Tei, Mitsuyoshi; Ikenaga, Masakazu; Kim, Ho Min; Osawa, Hideki; Takemoto, Hiroyoshi; Konishi, Ken; Uemura, Mamoru; Matsuda, Chu; Mizushima, Tsunekazu; Murata, Kohei; Ohno, Yuko; Doki, Yuichiro; Eguchi, Hidetoshi published the artcile< Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study>, Product Details of C20H21CaN7O7, the main research area is tegafur uracil leucovorin calcium adjuvant administration human colorectal cancer; Colorectal cancer; Leucovorin calcium; Phase III; Tegafur-uracil.

The 3-yr disease-free survival rate of the twice-daily regimen was not inferior to that of the conventional three-times-daily regimen, and the twice-daily regimen did not lead to an increase in adverse events. The effectiveness of the twice-daily regimen highlights an increased number of treatment options for patients. This will facilitate personalized medicine, particularly for elderly or frail patients who may experience more severe side effects from the combination therapy. Tegafur-uracil (UFT)/leucovorin calcium (LV) is an adjuvant chemotherapy treatment for colorectal cancer. We conducted a multicenter randomized trial to assess the noninferiority of a twice-daily compared with a three-times-daily UFT/LV regimen for stage II/III colorectal cancer in an adjuvant setting. Patients were randomly assigned to group A (three doses of UFT [300 mg/m2 per day]/LV [75 mg per day]) or B (two doses of UFT [300 mg/m2 per day]/LV [50 mg per day]). The primary endpoint was 3-yr disease-free survival. In total, 386 patients were enrolled between July 28, 2011, and Sept. 27, 2013. The 3-yr disease-free survival rates of group A (n = 194) and B (n = 192) were 79.4% and 81.4% (95% confidence interval, 72.6-84.4-74.5-85.9), resp. The most common grade 3/4 adverse events in group A and B were diarrhea (3.9% vs. 7.3%), neutropenia (2.9% vs. 1.6%), increase in aspartate aminotransferase (4.0% vs. 3.9%), increase in alanine aminotransferase (6.2% vs. 6.8%), nausea (1.7% vs. 3.4%), and fatigue (1.1% vs. 2.3%). Group B outcomes were not inferior to group A outcomes, and adverse events did not increase.

Oncologist published new progress about Anorexia. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Product Details of C20H21CaN7O7.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Lu, Linbin; Zhuang, Tingting; Shao, Erqian; Liu, Yanhong; He, Huimin; Shu, Zhimin; Huang, Yan; Yao, Yichen; Lin, Shan; Lin, Shaoqin; Chen, Xi; Chen, Xiong published the artcile< Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study>, Synthetic Route of 1492-18-8, the main research area is metastatic colorectal cancer bevacizumab chemotherapy antibiotic medication.

Preclin. studies showed that antibiotic exposure played a role in clin. outcomes in patients with chemotherapy via modulation of microbiota. However, it remains unknown whether antibiotic exposure during the bevacizumab therapy affects the clin. outcomes in metastatic colorectal cancer(mCRC) patients. This study aimed to examine the association between the antibiotic medication and the clin. outcomes in mCRC patients with bevacizumab therapy. This retrospective cohort anal. included 147 mCRC patients treated with bevacizumab. The hazard ratio of death was estimated using three Cox proportional hazards models with (1) never vs ever; (2) never vs 1-6 days and 7-40 days;(3) increase per day, and further tested using propensity score matching (PSM) and landmark anal. A smooth curve technique was used to explore the shape of dose-response relationship. Compared with the non-antibiotic group, antibiotic exposure was inversely associated with the mortality in the antibiotic group after adjustment for demog. and other potential confounders (a history of medication: HR, 0.650(95%CI: 0.360 to 1.173); an increase per day: HR, 0.967(CI: 0.924 to 1.011); 1-6 days: HR, 0.859(CI: 0.441 to 1.674); 7-40 days: HR, 0.474(CI: 0.225 to 0.999); P for trend = 0.040). A test for the interaction between sex was statistically significant (p = 0.016). A similar result was found as measured by landmark and PSM anal. Significant neg. dose-response relationship was shown by smooth curve anal. in the male patients but not female after adjustment for confounders(p = 0.028). No association was found between the antibiotic medication and adverse events of bevacizumab. Antibiotic exposure could be inversely associated with the mortality in mCRC patients treated with bevacizumab.

PLoS One published new progress about Antibiotics. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Synthetic Route of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Goksel, Yaman; Zor, Kinga; Rindzevicius, Tomas; Thorhauge Als-Nielsen, Bodil Elise; Schmiegelow, Kjeld; Boisen, Anja published the artcile< Quantification of Methotrexate in Human Serum Using Surface-Enhanced Raman Scattering-Toward Therapeutic Drug Monitoring>, Electric Literature of 1492-18-8, the main research area is surface enhanced Raman spectroscopy therapeutic drug monitoring methotrexate blood; methotrexate; patient samples; point-of-care detection; quantitative SERS; surface-enhanced Raman scattering; therapeutic drug monitoring.

Therapeutic drug monitoring (TDM) can improve clin. care when using drugs with pharmacokinetic variability and a narrow therapeutic window. Rapid, reliable, and easy-to-use detection methods are required in order to decrease the time of anal. and can also enable TDM in resource-limited settings or even at bedside. Monitoring methotrexate (MTX), an anticancer drug, is critical since it is needed to follow the drug clearance rate and decide how to administer the rescue drug, leucovorin (LV), in order to avoid toxicity and even death. We show that with the optimized nanopillar-assisted separation (NPAS) method using surface-enhanced Raman scattering, we were able to measure MTX in PBS and serum in the linear range of 5-150μM and confirmed that MTX detection can be carried out even in the presence of LV. Addnl., when NPAS was combined with centrifugal filtration, a quantification limit of 2.1μM for MTX in human serum sample was achieved. The developed detection method enables fast detection (10 min) and quantification of MTX from human serum (>90% accuracy). Furthermore, we show the potential of the developed method for TDM, when quantifying MTX from clin. samples, collected from patients who are undergoing high-dose MTX therapy.

ACS Sensors published new progress about Blood analysis. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Electric Literature of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Goksel, Yaman; Zor, Kinga; Rindzevicius, Tomas; Thorhauge Als-Nielsen, Bodil Elise; Schmiegelow, Kjeld; Boisen, Anja published the artcile< Quantification of Methotrexate in Human Serum Using Surface-Enhanced Raman Scattering-Toward Therapeutic Drug Monitoring>, Electric Literature of 1492-18-8, the main research area is surface enhanced Raman spectroscopy therapeutic drug monitoring methotrexate blood; methotrexate; patient samples; point-of-care detection; quantitative SERS; surface-enhanced Raman scattering; therapeutic drug monitoring.

Therapeutic drug monitoring (TDM) can improve clin. care when using drugs with pharmacokinetic variability and a narrow therapeutic window. Rapid, reliable, and easy-to-use detection methods are required in order to decrease the time of anal. and can also enable TDM in resource-limited settings or even at bedside. Monitoring methotrexate (MTX), an anticancer drug, is critical since it is needed to follow the drug clearance rate and decide how to administer the rescue drug, leucovorin (LV), in order to avoid toxicity and even death. We show that with the optimized nanopillar-assisted separation (NPAS) method using surface-enhanced Raman scattering, we were able to measure MTX in PBS and serum in the linear range of 5-150μM and confirmed that MTX detection can be carried out even in the presence of LV. Addnl., when NPAS was combined with centrifugal filtration, a quantification limit of 2.1μM for MTX in human serum sample was achieved. The developed detection method enables fast detection (10 min) and quantification of MTX from human serum (>90% accuracy). Furthermore, we show the potential of the developed method for TDM, when quantifying MTX from clin. samples, collected from patients who are undergoing high-dose MTX therapy.

ACS Sensors published new progress about Blood analysis. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Electric Literature of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Michel, Olga; Blasiak, Piotr; Saczko, Jolanta; Kulbacka, Julita; Drag-Zalesinska, Malgorzata; Rzechonek, Adam published the artcile< Electropermeabilization of metastatic chondrosarcoma cells from primary cell culture>, Electric Literature of 1492-18-8, the main research area is chondrosarcoma metastasis primary cell culture electropermeabilization; chondrosarcoma; electroporation; lung metastasis; primary cell cultures.

Primary cell cultures are challenging, but reliable model reflecting tumor response in vitro. The study was designed to examine if the increased electropermeabilization can overcame initial drug insensitivity in chondrosarcoma cells from lung metastasis. We established a primary cell culture and evaluated the cytotoxic impact of four drugs-cisplatin (CDDP), camptothecin, 2-methoxyestradiol, and leucovorin calcium (LeuCa). After determination of parameters allowing for electropermeabilization, we performed electrochemotherapy in vitro with the least toxic drugs-CDDP and LeuCa. Although combining CDDP and leucovorin together increased their toxicity and supported apoptosis, application of pulsed elec. fields (PEFs) brought no advantage for their efficacy. The study emphasizes the need for introduction of primary cell cultures into studies on pulse elec. fields as model frequently less sensitive to PEF-based treatments than continuous cell lines.

Biotechnology and Applied Biochemistry published new progress about Animal tissue culture, primary. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Electric Literature of 1492-18-8.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Pena-Cabia, Silvia; Royuela Vicente, Ana; Ramos Diaz, Ruth; Gutierrez Nicolas, Fernando; Penalver Vera, Angela; Siso Garcia, Isabel; Hitt Sabag, Ricardo; Garcia Lacalle, Concepcion; Pena-Cabia, Ana; Iglesias-Peinado, Irene; Garcia Diaz, Benito; Lopez-Martin, Ana published the artcile< Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer>, Recommanded Product: Calcium folinate, the main research area is human bevacizumab metastatic colorectal cancer exposure response relationship; Bevacizumab; Colorectal neoplasms; Drug monitoring; Exposure-response relationship; Treatment outcome.

Limited literature is available for bevacizumab exposure-response relationship and there is not a concentration threshold associated with an optimal disease control. This prospective observational study in patients with metastatic colorectal cancer (mCRC) aims to evaluate, in a real-life setting, the relationship between bevacizumab through concentrations at steady state (Ctrough, SS) and disease control. Ctrough, SS were drawn, coinciding with the radiol. evaluation of the response (progression or clin. benefit). Generalized estimating equations (GEE) anal. was performed. To test the association between Ctrough, SS in each patient with overall survival (OS) or progression-free survival (PFS), Cox proportional hazard models were developed. Data included 50 bevacizumab Ctrough, SS from 27 patients. The GEE model did not suggest any pos. association between bevacizumab Ctrough, SS and clin. benefit (OR 0.99, 95% CI: 0.98-1.02, p = 0.863). The Cox regression showed association between higher median Ctrough, SS with better OS (HR 0.86, 95% CI: 0.73-1.01, p = 0.060), but not with PFS. We cannot confirm a relationship between bevacizumab Ctrough, SS and clin. benefit but this is the first real-world study trying to show a relationship between bevacizumab Ctrough, SS and disease control in mCRC. It was conducted in a small sample size which reduces the level of evidence. Further controlled randomized studies with a sufficient number of patients are required.

Biomedicine & Pharmacotherapy published new progress about Body weight. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Recommanded Product: Calcium folinate.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts